Physicians' Academy for Cardiovascular Education

Diabetes & CVD

Diabetes type II confers an increased CVD risk. Recent scientific developments have yielded antidiabetic agents that positively impact CV risk in diabetic patients. Follow the latest insights into the close link between diabetes and CVD.

Prescribing and monitoring novel potassium binders for optimizing RAASi therapy in HF

10' education - Sep. 26, 2023 - Aaron Wong, MD

Healthy lifestyle interventions for CVD risk reduction in secondary prevention

3' education - Sep. 25, 2023 - Ruxandra Maria Christodorescu, MD and Nadia Bonekamp, MD

No increase of glucose levels with bempedoic acid

3' education - Sep. 4, 2023 - Kausik Ray, MD

Main messages of new ESC guidelines for CVD management in diabetes

3' education - Aug. 29, 2023 - Nikolaus Marx, MD

Clinically meaningful benefits with GLP-1RA in HFpEF and obesity

3' education - Aug. 25, 2023 - Mikhail Kosiborod, MD

Polypharmacy: Adding nonsteroidal MRAs, when and how

10' education - July 24, 2023 - Tessa Laubscher, MD, George L. Bakris, MD, and Mikhail Kosiborod, MD

Optimizing therapy for a patients with T2D and early-stage CKD

10' education - July 20, 2023 - Tessa Laubscher, MD, George L. Bakris, MD, and Mikhail Kosiborod, MD

Nonsteroidal MRA as a therapeutic option in patients with T2D and CKD

10' education - July 17, 2023 - Tessa Laubscher, MD, George L. Bakris, MD, and Mikhail Kosiborod, MD

Elevated inflammation markers in diabetes: a cause or a consequence?

3' education - May 23, 2023 - Peter Libby, MD

Identifying and treating iron deficiency in heart failure

10' education - Nov. 17, 2022 - Robert J. Mentz, MD & Prof. Peter van der Meer, MD, PhD

Optimizing GDMT in HFrEF and management of hyperkalemia

10' education - Nov. 17, 2022 - Prof. Mikhail Kosiborod, MD

Reducing morbidity and mortality in patients with CKD and T2DM

10' education - Nov. 14, 2022 - Pam Taub, MD, Prof. George Bakris, MD, and Prof. Gerasimos Filippatos, MD

A new option for cardiorenal protection for patients with CKD and T2DM

10' education - Nov. 14, 2022 - Prof. Gerasimos S. Filippatos, MD, Javier Morales, MD, and Angela Yee-Moon Wang, MD, PhD

Identification and management of patients with HFpEF and diabetes

10' education - Oct. 26, 2022 - Prof. Silvio Inzucchi, MD & Prof. Pardeep Jhund, MD, PhD

HFpEF and diabetes: What are the clinical challenges?

10' education - Oct. 25, 2022 - Prof. Pardeep Jhund, MD, PhD

SGLT2i in HFmrEF and HFpEF across the spectrum of glycemia

10' education - Oct. 24, 2022 - Prof. Silvio Inzucchi, MD

The spectrum of therapeutic options: which therapies to consider?

10' education - Oct. 18, 2022 - Prof. Ulf Landmesser, MD

2022 ADA/EASD consensus report on management of hyperglycemia in T2DM

3' education - Sep. 29, 2022 - Prof. John Buse, MD, PhD

SGLT2i reduces outcomes in HFmrEF and HFpEF regardless of glycemic status

3' education - Sep. 22, 2022 - Prof. Pardeep Jhund, MD, PhD

Consistent beneficial effect with GLP-1RA across broad range of kidney function and kidney damage

3' education - Sep. 21, 2022 - Prof. Peter Rossing, MD

Triglycerides most commonly a marker of ectopic fat accumulation

5' education - July 20, 2022 - Prof. Naveed Sattar, MD, PhD

Primary care as gatekeeper in CKD and the need for collaboration with nephrologists

10' education - July 13, 2022 - Prof. Kamlesh Khunti, MD, PhD

Discussion - Preventing CKD in patients with diabetes - Exploring the current and future role of GLP-1RA

10' education - July 6, 2022 - Prof. Johannes Mann, MD, prof. Filip Knop, MD, PhD, and prof. Katherine Tuttle, MD

Why is early screening and risk identification of CKD in diabetes important?

10' education - July 6, 2022 - Rikke Borg, MD, PhD

Clinical dialogue: Lowering ASCVD risk in a patient with T2DM and obesity

15' education - July 5, 2022 - Prof. Nikolaus Marx, MD and Adie Viljoen, MD

Barriers for preventing CKD in patients with diabetes

10' education - June 28, 2022 - Prof. Christoph Wanner, MD

Clinical dialogue: CV risk in diabetes

15' education - June 22, 2022 - Prof. Nikolaus Marx, MD and Michael Lehrke, MD

Which patients with CKD and diabetes will benefit from management with GLP-1RA?

10' education - June 13, 2022 - Prof. Katherine Tuttle, MD

What is relevant for nephrology with regard to GLP-1RA in CVD?

10' education - June 10, 2022 - Prof. Filip Knop, MD, PhD

GLP-1RA as new treatment option on the horizon for obesity

3' education - May 31, 2022 - Prof. Ulrich Laufs, MD, PhD

Prescribing and monitoring novel potassium binders for optimizing RAASi therapy in HF

10' education - Sep. 26, 2023 - Aaron Wong, MD
Hyperkalemia is a predictable, treatable, and manageable condition, according to Aaron Wong. He shares his practical experience to manage the risk of hyperkalemia using a novel potassium binder, which allows for the optimization of RAASi therapy in HF.

Hyperkalemia is a predictable, treatable, and manageable condition, according to Aaron Wong. He shares his practical experience to manage the risk of hyperkalemia using a novel potassium binder, which allows for the optimization of RAASi therapy in HF.

GLP-1RA effective in obesity phenotype of HFpEF, regardless of obesity class

Literature - Sep. 25, 2023 - Borlaug BA, et al. - Nat Med. 2023

In a prespecified analysis of the STEP-HFpEF trial among patients with the obesity phenotype of HFpEF, semaglutide reduced body weight and HF-related symptoms and signs compared with placebo across all 3 obesity categories.

Healthy lifestyle interventions for CVD risk reduction in secondary prevention

3' education - Sep. 25, 2023 - Ruxandra Maria Christodorescu, MD and Nadia Bonekamp, MD
**ESC Congress 2023** How do healthy lifestyle interventions fit in the current therapeutic landscape for patients with established CVD? Nadia Bonekamp interviews Ruxandra Maria Christodorescu about this topic.

ESC Congress 2023 How do healthy lifestyle interventions fit in the current therapeutic landscape for patients with established CVD? Nadia Bonekamp interviews Ruxandra Maria Christodorescu about this topic.

Consistent benefit of SGLT2 inhibitors on CV outcomes across various patient populations

Literature - Sep. 21, 2023 - Usman MS, et al. - J Am Coll Cardiol. 2023

What are the effects of SGLT2 inhibitors on CV outcomes across different subgroups of patients? This was investigated in a meta-analysis of 13 RCTs in patients with HF, T2D or CKD, and in patients with varying combinations of these diseases.

Greater cardioprotective effects of nonsteroidal MRA in CKD and T2D patients with anemia

News - Sep. 5, 2023

ESC Congress 2023 A post-hoc analysis of FIDELITY showed that baseline anemia status modifies the effect of finerenone on cardiovascular outcomes, but not renal outcomes, in patients with CKD and T2D.

No increase of glucose levels with bempedoic acid

3' education - Sep. 4, 2023 - Kausik Ray, MD
Kausik Ray summarizes the findings of a pre-specified analysis of the CLEAR Outcomes trial in which the efficacy and safety of bempedoic acid was examined in patients with normoglycemia, prediabetes and diabetes.

ESC Congress 2023 Kausik Ray summarizes the findings of a pre-specified analysis of the CLEAR Outcomes trial in which the efficacy and safety of bempedoic acid was examined in patients with normoglycemia, prediabetes and diabetes.

Main messages of new ESC guidelines for CVD management in diabetes

3' education - Aug. 29, 2023 - Nikolaus Marx, MD
Nikolaus Marx presents the main messages of the 2023 ESC Guidelines for the management of CVD in patients with diabetes.

ESC Congress 2023 Nikolaus Marx presents the main messages of the 2023 ESC Guidelines for the management of CVD in patients with diabetes.

Bempedoic acid does not increase risk of glycemia or new onset diabetes

News - Aug. 28, 2023

ESC Congress 2023 A prespecified analysis of the CLEAR Outcomes trial investigated whether trial data of bempedoic acid are concordant with genetic data for ACLY inhibition with regard to CV risk reduction, glycemia and risk of new onset diabetes.

Clinically meaningful benefits with GLP-1RA in HFpEF and obesity

3' education - Aug. 25, 2023 - Mikhail Kosiborod, MD
**ESC Congress 2023 ** The STEP HFpEF trial shows that semaglutide improves HF-related symptoms and leads to greater weight loss in patients with HFpEF. “Collectively, these findings indicate that semaglutide is a valuable treatment option in patients with HFpEF and obesity” says Mikhail Kosiborod.

ESC Congress 2023 The STEP HFpEF trial shows that semaglutide improves HF-related symptoms and leads to greater weight loss in patients with HFpEF. “Collectively, these findings indicate that semaglutide is a valuable treatment option in patients with HFpEF and obesity” says Mikhail Kosiborod.

GLP-1RA improves HF symptoms and physical function in patients with HFpEF and obesity

News - Aug. 25, 2023

ESC Congress 2023 STEP HFpEF showed that once-weekly semaglutide 2.4 mg improved HF-related symptoms, physical limitations and exercise function, and led to greater weight loss in patients with HFpEF and obesity, compared with placebo.

Phase 3 trial with GLP-1RA in adults with overweight or obesity meets primary endpoint

News - Aug. 8, 2023

In the SELECT trial, treatment with the GLP-1RA semaglutide reduced the risk of MACE in adults with overweight or obesity and established CVD.

Loneliness associated with higher CVD risk in DM

Literature - Aug. 3, 2023 - Wang X, et al. - Eur Heart J. 2023

A population-based cohort study showed that loneliness, but not social isolation, was associated with a higher CVD risk in patients with DM. Loneliness also ranked higher in relative strength for predicting CVD risk than lifestyle risk factors such as smoking and diet.